Tyrosine News and Research

RSS

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.

16 Dec 2014

Postoperative recurrent disease affects NSCLC survival after gefitinib

Patients with postoperative recurrent non-small-cell lung cancer harbouring epidermal growth factor receptor mutations have longer progression-free and overall survival with gefitinib treatment, than those with stage IV disease, Japanese researchers report.

15 Dec 2014

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco.

13 Dec 2014

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Adding the novel insulin-like growth factor 1 receptor inhibitor figitumumab to the epidermal growth factor receptor–tyrosine kinase inhibitor erlotinib does not improve survival in patients with non-adenocarcinoma non-small-cell lung carcinoma, research shows.

12 Dec 2014

Postoperative recurrent disease affects NSCLC survival after gefitinib

12 Dec 2014

First-line dacomitinib may improve advanced NSCLC survival

Preliminary research suggests that the second-generation tyrosine kinase inhibitor dacomitinib may improve progression-free survival in patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations.

11 Dec 2014

Molecular response criteria examined for CML

The limitations in determining molecular response in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitor therapy have been reviewed in Cancer.

9 Dec 2014

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates.

9 Dec 2014

Ponatinib ‘superior’ to sequential second-generation TKI treatment in CML

Patients with chronic myelogenous leukaemia resistant or intolerant to at least one second-generation tyrosine kinase inhibitor have a higher probability of achieving a response to the third-generation TKI ponatinib than to a further second-generation TKI, research indicates.

9 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM).

7 Dec 2014

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT).

5 Dec 2014

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London.

4 Dec 2014

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast and colon cancers, according to two studies led by researchers at the Icahn School of Medicine at Mount Sinai and published today in the Proceedings of the National Academy of Sciences.

2 Dec 2014

VE-PTP potential treatment target for retinal and choroidal vascular diseases

Targeting vascular endothelial-protein tyrosine phosphatase, which negatively regulates TIE2 activation, could help to stabilise retinal and choroidal blood vessels, researchers report.

1 Dec 2014

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics, Inc.today announced the acceptance of a Type II variation application for IMBRUVICA (ibrutinib) by the European Medicines Agency.

1 Dec 2014

Plymouth professor awarded grant to find effective treatment for patients with mantle cell lymphoma

Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer Research UK to carry out a research study into the treatment of older patients with mantle cell lymphoma.

27 Nov 2014

Dacomitinib ‘not superior’ to erlotinib in advanced NSCLC

Dacomitinib, an irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor, does not improve outcomes compared with the first-generation EGFR–TKI erlotinib in patients with advanced non-small-cell lung cancer, irrespective of their KRAS mutation status, finds the ARCHER 1009 study.

24 Nov 2014

Tyrosine News and Research

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

Postoperative recurrent disease affects NSCLC survival after gefitinib

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Postoperative recurrent disease affects NSCLC survival after gefitinib

First-line dacomitinib may improve advanced NSCLC survival

Molecular response criteria examined for CML

PD-1, PD-L1 differentially expressed in NSCLC

Ponatinib ‘superior’ to sequential second-generation TKI treatment in CML

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Novel targeted therapies and treatment combinations for leukemia

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

VE-PTP potential treatment target for retinal and choroidal vascular diseases

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Plymouth professor awarded grant to find effective treatment for patients with mantle cell lymphoma

Dacomitinib ‘not superior’ to erlotinib in advanced NSCLC

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News